Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha-fetoprotein small interfering RNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Alpha-fetoprotein small interfering RNA (AFP-siRNA) is an RNA interference (RNAi) therapeutic designed to specifically target and silence the expression of the alpha-fetoprotein (AFP) gene. AFP is a glycoprotein normally produced during fetal development but is frequently overexpressed in hepatocellular carcinoma (HCC), where it serves as a diagnostic biomarker and a driver of tumor progression. By delivering siRNA sequences complementary to AFP mRNA—often encapsulated in delivery vehicles like polylactic-co-glycolic acid (PLGA) nanoparticles—the drug triggers the catalytic degradation of the target mRNA, thereby reducing AFP protein levels. Research indicates that AFP-siRNA can inhibit tumor cell proliferation and may work synergistically with multi-kinase inhibitors such as sorafenib or sunitinib to enhance anti-tumor activity in liver cancer models.
- Other names
- AFP siRNAalpha-fetoprotein siRNA
02
Targets
AFP (Alpha-fetoprotein)
Beyond the preview
Go deeper on alpha-fetoprotein small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpha-fetoprotein small interfering RNA.